PHENYLephrine Injectable Syringe Recall Due to Insufficient Sterility Assurance
Central Admixture Pharmacy Services recalls 499,304 PHENYLephrine syringes nationwide because validation data for sterility decontamination cycles was lacking. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Class II FDA recall of a sterile injectable product with inadequate validation of sterilization decontamination cycles. No illnesses or injuries reported. Per the rubric, a high-risk product without reported harm scores 3 (High).
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 499,304 pre-filled syringes of PHENYLephrine 1,000 mcg/10mL (100 mcg/mL in 0.9% sodium chloride), distributed nationwide. This is a prescription-only injectable medication.
The recall was initiated due to lack of assurance of sterility. Validation data for the decontamination cycles used in manufacturing was lacking, indicating the sterilization process had not been adequately validated.
Multiple lots with expiration dates from July 10, 2023 through September 6, 2023 are affected.
The recalled product
- Product
- PHENYLephrine 1,000 mcg/10mL, (100mcg/mL) in 0.9% sodium chloride, Syringe, Rx Only, CAPS, Inc., 2200 South 43rd Avenue, Phoenix, AZ 85043, NDC: 72196-6009-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Hazard
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 36-239063
- 36-239064
- 36-239065
- 36-239066
- 36-239067
- 36-23906
- 736-239068
- 36-239069
- 36-239204
- Exp. 7/10/2023
- 36-239196
- 36-239197
- 36-239198
- 36-239199
- 36-239200
- 36-239201
- 36-239202
- 36-239203
- 36-239205
- 36-239206
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27